#1TO IMPROVE THE LIVES OF PATIENTS WITH SERIOUS CNS DISORDERS Corporate Presentation ASX: BNO OTCQB: BNOEF December 2021 CONFIDENTIAL Bionomics#2SAFE HARBOR STATEMENT 2 Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC 105, BNC 101 and BNC375), its licensing agreement with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing arrangements, delays or difficulties associated with conducting clinical trials, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third party sources and Bionomics' own internal estimates and research. While we believe these third party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Bionomics has filed a registration statement (including a preliminary prospectus) with the Securities and Exchange Commission ("SEC") for the offering to which this communication relates. The registration statement has not yet become effective. Before you invest, you should read the prospectus in the registration statement and other documents Bionomics has filed with the SEC for more complete information about Bionomics and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at http://www.sec.gov. Alternatively, Bionomics, any underwriter, or any dealer participating in the offering will arrange to send you the prospectus if you request it from (1) Evercore Group LLC., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474-0200, or by email at [email protected]; or (ii) William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, or by telephone at (800) 621-0687 or by email at [email protected]. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Bionomics#3Offering Summary Issuer Ticker / Exchange Gross Proceeds Option to Purchase ADSS Use of Proceeds Lock-Up Period Active Bookrunners Expected Pricing Bionomics PTSD = Post-Traumatic Stress Disorder Represents ADS ratio of 180 Bionomics Limited BNOX / Nasdaq Global Market -$25.0 million (1,620,000 ADS, 100% primary, excluding over-allotment) -$3.75 million (15% of the offering ADSS) To advance BNC210 into a Phase 2 trial for the acute treatment of Social Anxiety Disorder (SAD), including the initiation and completion of the planned Phase 2 PREVAIL clinical trial H The continued development of BNC210 for the treatment of PTSD, including completion of the ongoing Phase 2b ATTUNE clinical trial E The completion of chemistry, manufacturing and controls, long term safety and non-clinical pharmacology studies necessary to support Phase 3 pivotal trials of BNC210 for the treatment of SAD and PTSD Working capital and other research and development and general corporate purposes 180 days for the Company, directors, executive officers and certain shareholders Evercore ISI, William Blair Week of December 13, 2021 3#4Emerging Leader in Neuropsychiatry Bionomics Diversified, clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious Central Nervous System (CNS) disorders 1 alı BNC210 entering Phase 2 for acute treatment in Social Anxiety Disorder (SAD)- Established clinical PoC in GAD¹ and Fast Track designation from FDA for SAD BNC210 in ongoing Phase 2b ATTUNE trial with Fast Track designation from FDA for PTSD Large underserved markets with over 22 million patients in the United States alone suffering from SAD and PTSD and no new FDA approved therapies in nearly two decades 4 Strategic partnership with Merck & Co. for cognitive impairment in Alzheimer's disease and other CNS conditions Pipeline of partnering candidates targeting potassium (Kv) and sodium (Nav) ion channels Well-capitalized balance sheet with multiple potential near term value-driving milestones of Concept Bionomics GAD-Generalized Anxiety Disorder PTSD-Post-Traumatic Stress Disorder Wise et al 2020, Biological Psychiatry Perkins et of 2021, Molecular Psychiatry#5Powered by a Seasoned and Experienced Management Team Archemix Aventis BIODEL Bionomics Errol De Souza, PhD Executive Chairman Liz Doolin VP Clinical Development CATALYST BIOSCIENCES cyclerion Groumvent Pharma Deloitte. T Logos reflect experience in cument and/or post ros DUPONT IDEXX LABORATORIES LINK NOTHERAPEUTIC Connor Bernstein VP Strategy & Corporate Development Adrian Hinton Interim Chief Financial Officer Neurocrine PIPER SANDLER ROYALTY PHARMA RBC Capital Markets Synaptic NEUROPORE THERAPIES PALATIN Pharma Ltd. BOARD OF DIRECTORS ¹ Errol De Souza PhD Executive Chairman David Wilson Non-Executive Director Alan Fisher Non-Executive Director Jane Ryan PhD Non-Executive Director Mitchell Kaye BVF Nominee Aaron Weaver Apeiron Nominee Miles Davies Apeiron Nominee Bionomics Vpartners PiperJaffray Coopers &Lybrand ANATARA BCAL DEEP TRACK CAPITAL BVF APEIRON INVESTMENT GROUP atai A&O APEIRON INVESTMENT GROUP Rothschild & Co 5#6Wholly-Owned Collaboration Focused CNS Pipeline with Multiple Potential Catalysts on the Horizon PROGRAM BNC210 a7 receptor NAM EmpathBio BNC210 MERCK COLLABORATION a7 receptor PAM PRECLINICAL PHASE 1 Post-Traumatic Stress Disorder (PTSD) ATTUNE Study 200 patients, -25 centers in US Social Anxiety Disorder (SAD) PREVAIL 150 patients, -15 centers in US PHASE 2 +MDMA derivative Memorandum of Understanding to explore EMP-01 (PTSD) combination treatment regimen for PTSD 2 candidates for cognitive deficits in Alzheimer's Disease NAM Allosteric Modulator Bionomics PAM-Positive Allesteric Modulator PHASE 3 EXPECTED TIMING Study underway Topline Data: 1H'23 Starting Ph2: YE'21 Topline Data: YE'22 Ongoing Ph1 Safety & biomarker studies ongoing 6#7A Differentiated Approach: The a7 Nicotinic Acetylcholine Receptor 3 Normalizing Effect Utilizing Allosteric Modulation 2 1 Channel opens: ACh binds to a7 receptor orthosteric sites 00000 PAMS/NAMS bind to a7 receptor allosteric sites Bionomics Ca Poooooooooo Ca² Co-Calcium ACH- Acetylcholine NAM-Negative Aloten Modulator PAM-Positive Asteric Modulator Ca²+ flow through the channel when CAS-Cognitive impament Associated with Schumphrenic JONO Attention Date a7 receptors are activated Transmembrane Binding Domain Allosteric drug transmembrane binding domain restores normal activity Cholinergic System associated with memory selective attention, and emotional processing cognitive functions PTSD-Post-Traumotic Stress Disorder Targeting Distinct CNS Conditions with Neurotransmitter Imbalance Hypercholinergic Disease States PAM Indications +Alzheimer's Bionomics NORMAL ACTIVITY + CIAS + ADHD BNC210 (NAMS) + Anxiety + PTSD + Depression 7 Hypocholinergic Disease States#8Harnessing the Power of a Novel Neuromodulatory Mechanism 잇 Action of BNC210 depends on Acetylcholine neurotransmission and Allosteric Modulation of a7 nACHR Bionomics AACR iconic Acetylcholine Receptor NAM-Negative Adostric Modulator Co-Calcium ion ACh-Acetylcholine Fr Hippocampus Prefrontal Cortex- Forebrain ACH Ca Amygdala NORMAL BNC210 a7nACH Receptor INFLUX NORMAL MOOD Hippocampus Prefrontal Cortex Basal Forebrain Amygdala ANXIETY & PTSD MOOD DISORDERS BNC210 INFLUX 0:0 INFLUX BNC210 RESTORES NORMAL MOOD NAMS have self-limiting activity determined by the cooperative interaction between BNC210 and Acetylcholine binding at the allosteric and orthosteric sites, respectively 8#9Bionomics lin BNC210 in Social Anxiety Disorder 21 S 9#10Targeting a Large Segment of the Anxiety Market Acute Anxiety in SAD Represents a Significant Unmet Need Social Anxiety Disorder (SAD), or Social Phobia, is a significant and persistent fear of social and performance-related situations ii . Includes anxiety from everyday social situations as well as "Fear of Public Speaking" A disorder that substantially impacts many people's daily lives Amongst the largest mental health conditions with lifetime prevalence affecting >31M Americans No FDA-approved fast-acting medications for as-needed treatment Medications with the right pharmacokinetic profile and a novel mechanism are needed -31M 12.1% of adults at some point in their lives -18M 7.1% prevalence in adults Unmet medical need to large patient population Advancement in care No FDA-approved fast-acting competition Ability to potentially achieve large market share Sources NIMH Social Anxiety Disorder' dato from 2017 National Comorbidity Survey (NCS) https://www.imh.nih.gow/health/statistics/social-anxiety-disorder.shtml Anxiety and Depression Association of Americo (ADAA) Social Anxiety Disorder- uinderstand the Facts' https://odas.org/understanding anxiety/social-anniety-disorder Bionomics Atril ~7M 36% of adults > 10 years SAD symptoms Opportunity for BNC210 10#11BNC210 Observed to Significantly Reduce Panic Symptoms in Humans: CCK-4-Induced Model Placebo- controlled study in 15 healthy volunteers who experienced a CCK-4-induced panic attack Bionomics Panic Symptom Scale (% of Placebo) 100 90 80 70 40 30 20 10 Total # of Panic Symptoms I -37.7% (p<0.048) CCR-4 = Cholecystokinin Tetrapeptide (o peptide that induces anxiety and panic symptoms) Panic Symptom Scale (% of Placebo) Placebo 100 90 70 60 50 30 20 10 Panic Symptom Intensity BNC210 -52.7% (p<0.041) BNC210 demonstrated statistically significant reduction in both number and intensity of panic symptoms measured with the Panic Symptom Scale 11#12BNC210 Phase 2 in GAD Observed to Have Acute Anxiolytic Activity 300 mg 24 GAD Patients 4 WAY CROSSOVER Significantly reduced activation of Em L&R amygdala caused by viewing fearful faces (L: p<0.05; R: p<0.01) BNC210 300 mg BNC210 2000 mg Lorazepam 1.5 mg Placebo Contrast estimate Significantly reduced connectivity (()) between amygdala and ACC while viewing fearful faces (p<0.05) 1.0 0.8 0.6 0.4 0.2 0.0 -0.2 Placebo Seed hemisphere Left Right Fearful Faces 300 mg fMRI Monitoring 0.5- Significantly reduced threat avoidance behavior of anxious subjects in the JORT behavioral task Mean Intensity of Defensive Behavior 0.4- 0.3- 0.2- 0.1- 0.0 Performed 'JORT' Placebo P=0.165 P=0.007 Lorazepam Error Bors= SEM 300 mg -BNC210 Bionomics seta Bological Psychiatry 2020 fhttps://doi.org/10.1016/4biopsych 2019 12012) Perkins A et al, Translational Psychiatry 2021 (Ittps://dokorg/10.1038/54-1398 -020-01141-51 GAD-Generalized Anxiety Disorder JORT=Joystick Operated Runway Task MRI Functional Magnetic Resonance imaging Amygdala activation is an imaging surrogate for anxiety Connectivity between the amygdala and Anterior Cingulate Cortex (ACC) is very strong in high anxiety P=0.033 2000 mg 12#13BNC210 Potentially Addresses the Shortcomings of Existing Social Anxiety Disorder Approaches 13 Novel Mechanism of Action Potential Large Market Potential for Social Anxiety Disorder Bionomics BNC210 Potential for Acute Treatment in Social Anxiety Disorder Patients Anti-Anxiety Effects In healthy subjects (anti-panic) and GAD patients (anti-anxiety) Attractive Clinical & Regulatory Pathway Rapid Onset of Action CURRENT THERAPIES FOR THE TREATMENT OF ANXIETY AND STRESSOR-RELATED DISORDERS* DRUG FAST ACTING Benzodiazepines ✔ NO NO NO WITHDRAWAL NO MEMORY MOTOR SEDATION SYNDROME IMPAIRMENT IMPAIRMENT X X X X SSRIs/SNRIS X ✔ X ✔ ✔ BNC210 IS DESIGNED TO PROVIDE POTENTIAL ADVANTAGES COMPARED TO CURRENT THERAPIES* *Potential benefits based on analysis of data prom separate studies are not on results that have been obtained from head-to-head studies Such das may not be directly comparable due to offerences in shady protocols condicions and patient populations Accordingly cross-treal compansans may not be able predictors of the relative activity or other benefits of BNC2 10 compared to existing theraps or other product candidates that may be approved or are in development for the treatment of PTSD or SAC The potential benefits of BMC210 does not imply an expectman of regulatory approval which is solely within the authority of the FDA for applicable for regasto T includes Values and certae other benzodiazepines includes Prator and certain other SSR elective Senatonin Reuptake inhibitor/ Beraton-orepinephine napake inhibitor#14· wwwww BNC210's Rapid Onset of Action is Potentially Well-Positioned for Social Anxiety Disorder Emerging Regulatory Landscape & Unmet Need No fast-acting FDA-approved medications for as-needed treatment of SAD Benzodiazepines prescribed off-label have significant side effects of sedation, cognitive impairment and potential for addiction Growing unmet need based on improving awareness and evolving social dynamics FDA precedent on simplified public speaking challenge endpoint for acute anxiety reduction vs. placebo* Bionomics "Based on path of CNS peer proceeding with registrational Phose 3 endpoint Rapid Onset of Action with BNC210 Formulation Clinically demonstrated potential for reducing anxiety in acute treatment of GAD patients and following panic induction Observed acute anxiolytic efficacy of BNC210 similar to lorazepam without sedative properties and addiction liability Formulation potentially well-suited for acute dosing - Rapidly absorbed to high concentrations within a short period of time √ Maximum concentrations reached in -45-105 min. across the dose range Concentration ng/ml 5000- 4000- D T 2 E 161 Concentration versus Time 1200 mg tablert fasted 900 mg tablet fasted 1:8 T 10 Time (hours) 800 mg tablet fo 16 T 18 T 20 14 T#15BNC210 Phase 2 Social Anxiety Disorder Trial Social Anxiety Disorder Study Highlights ✓ Potential to conduct a cost-effective trial with an efficacy endpoint conducive to rapid data generation ✓ Ability to leverage development strategies of other Social Anxiety Disorder public CNS trial designs Received FDA clearance for IND filing and FDA Fast Track designation Phase 2 trial on target to start by end of 2021 and read out topline data by end of 2022 Bionomics Phase 2 Acute Social Anxiety Disorder PREVAIL Study Design Screening -50 225 mg BNC 210 60m LSAS = 70 Randomization (Double-blind) 50 -50 675 mg BNC 210 60min SINGLE ANXIETY CHALLENGE Årsase PLACEBO -50 FDA Fast Track designation 60mm PREVAIL Study 15 LIEBOWITZ SOCIAL ANXIETY SCALE >95: Very severe social phobia 80-95: Severe social phobia 65-80: Marked social phobia 55-65: Moderate social phobia ↓ EFFICACY ENDPOINT SUBIECTIVE UNITS OF DISTRESS SCALE (SUDS): Measures the self-reported intensity of anxiety and/or distress in SAD patients Topline data expected YE'22#16BNC210 in Post-Traumatic Stress Disorder 2 Bionomics 16#17Tackling the Profound Disease Burden of Post-Traumatic Stress Disorder PTSD Represents a Significant Unmet Need ✓ 70% of people will experience a traumatic event in their lifetime, but most people recover normally ✓ PTSD results from exposure to actual or threatened death, serious injury or sexual violence ✓ PTSD affects up to 8% of adults during their lifetime¹ PTSD is a global mental health problem that is associated with significant morbidity and mortality and shows up in all facets of peoples' lives ✓ No newly approved pharmacotherapy in almost two decades Medications with a novel mechanism of action that can address the pathophysiology of PTSD are needed ~21M 8% of adults at some point in their lives ~9M 3.4% prevalence in adults Unmet medical need to large patient population Advancement in care No branded competition Ability to potentially achieve large market share Deck H, Mion, M, Miller, M, Weyes and Friedman M, 2013 Nation Estates of Exposure to Troumatic Events and PTSD Prevalence Using DSM-ly and DSM-5 Gr Bionomics Journal of Traumatic Stress 2605, pp537-5422 My LM Asration A. Lande/et at Elevated Anondomide Enhanced Recall of Fear Extinction and Attemated Stress Responses Following inhibition w/ Fatty Acid Amide Hydrolase A Rundanteed Contred Experimental Medicine Trial Bol Psychiatry 2020 M 15,876 536-54 Only 20 to 30% of PTSD patients achieve cinsicol remisionon SSR therapes US Census Bureau //www.census.go/library/ses/2021/08/united-stones-out-population grew foster-than-nations-total population from 2010 to 2020 -7M 75% of adults inadequately treated Opportunity for BNC210 17#18BNC210 Anti-Anxiety Signals Observed in Animal Models and Human Translational Studies of @ People with anxiety disorders and PTSD have amplified fear responses to trauma-or stress-related stimuli and impaired fear extinction Time Spent Freezing (sec) G Conditioned Fear Extinction Model 175 150- 125- 100- 75- 50 25- 10 T T Diazepam (0.5 mg/kg) Vehicle BNC210 (100 mg/kg) p=0.03 p = 0.01 Days after Conditioning BNC210 enhanced fear extinction following conditioned response training "Time in minutes ofter CC-4 injection Bionomics CCK-4-Cholecystokinin Tetrapeptide to peptide that induces anxiety and ponic symptoms) eMAS = Emotional Visual Analog Scole eVAS Score Emotional Visual Analog Scale (eVAS) 10 -10 -20 -30 Recovery to Baseline OBNC210 1 5 10 15 20 60 Placebo Recovery to Baseline 5 10 15 20 60 Minutes (Post-Panic Attack)* BNC210 enhanced emotional recovery following a CCK-induced panic attack 18#19BNC210 Potentially Addresses the Shortcomings of Existing PTSD Therapies Proof of Biology In healthy subjects (anti-panic) and GAD patients (anti-anxiety) Novel Mechanism of Action Bionomics BNC210 Potential to treat PTSD and Other Trauma and Stress-Related Disorders Demonstrated Target Engagement At nicotinic receptor in healthy subjects Large Market Potential For treatment of multiple psychiatric indications Strong Safety Database In humans - 12 clinical trials, exposure in -400 subjects DRUG CURRENT TREATMENTS FOR PTSD NO FAST WITHDRAWAL NO MEMORY ACTING SEDATION SYNDROME IMPAIRMENT IMPAIRMENT NO NO MOTOR X ✔ SSRIs/SNRIS X BNC210 IS DESIGNED TO PROVIDE POTENTIAL ADVANTAGES COMPARED TO CURRENT THERAPIES* "Potential benefits bosed on analysis of data from separate studies ond not on results that night have been obtained from head to head studies Such dots may not be directly comparable due to differences e shady protocols conditions and patient populations Accordingly cross-to comparisons may not be able predictors of the relative efficacy or other benefits of BMC210 compared to existing therapies or other product candidates that may be approved or care in development for the treatment of PTSD or SAD 1 ces Pac and certain other See Serotonin Reuptake inhibit/SAR (Serotonin-Norening Rekenin 19#20BNC210 is Potentially Well-Positioned in Post-Traumatic Stress Disorder restore Anti-depressant and anti-anxiety trends seen at earlier time points ✓Safety profile generall well tolerated Did not meet primary endpoint"; lower than expected exposure of liquid suspension formulation Bionomics NHA ✓New tablet formulation overcomes food effect of suspension formulation ✓ Achieved exposure target predicted from pharmacometric analysis ✓ Extended IP coverage Pharmacometric analysis of Phase 2 PTSD data ✓Predicted significant efficacy potential with adequate drug exposure achieved *Primary endpoint of CAPS-5 total symptom severity score at 12 weeks FDA Type C meeting with FDA ✓ FDA granted Fast Track designation in PTSD ATTUNE Study ✓ Phase 2b ATTUNE trial started in July 2021 ✓ Topline data expected 1H 2023 20#21Pharmacometric Modeling Target Achieved with New Dose Solid Formulation PMX modelling on prior Phase 2 PTSD trial identified liquid suspension under-exposure BNC210 tablet formulation New formulation achieves target AUC >25 mg.hr/L with 900 mg dose bid Pharmacometric (PMX) Analysis Target Exposure RESPONSE (A from Placebo) 10 10 AUC Values (plasma exposure) Bionomics Population phamoxometic modding buid-Administered bakedbly EXPOSURE- RESPONSE CURVE (BASELINE CAPS-5 TOTAL SCORE OF 30) AUC90 25 mg.hr/L EXPOSURE: AUC (mg.hr/L) 7-Day Pharmacokinetic study of BMC2 10 tablet formulationen AUC (mg) standard deviation 7-Day PK Trial New tablet formulation In-clinic setting CAPS-5 Score (PTSD symptoms) 60 BNC210 Novel Spray Dry Dispersion Formulation BNC210 ng/ml 1750- 1500- 1250- 1000- 750- 500- 250- D 01234 300 mg Solid Dose Tablet Fasted High Fat Meal 6 8 10 12 Time (Hr) 18 20 21 Novel tablet overcomes food effect and has dose linear exposure 24#22BNC210 Phase 2b PTSD ATTUNE Study Underway WEEK1 2 3 4 5 6 7 OUTPATIENT BID DOSING Phase 2B 1:1 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED BNC210 MONOTHERAPY IN PTSD PATIENTS -200 Subjects BNC 210 900 mg oral tablet PLACEBO 8 9 SECONDARY ENDPOINTS Various patient-reported symptoms of PTSD, changes in anxiety and depression symptoms, and global and social functioning: Safety & tolerability endpoints 10 11 12 FOLLOW-UP PRIMARY ENDPOINT Investigator-rated PTSD symptoms on CAPS-5 Total Symptom Severity Scores in change from Baseline to Week 12 compared to placebo Fast Track designation from FDA BID-Twice dolly dosing Bionomics CAPS-S-Clinicion Administered P750 Scole for the Diagnostic and Stonitical Manual of Mental Disorders, Sch Edition (DSM-S) 15 ATTUNE Study 22 PHASE 2B Single potential registrational- supporting trial for monotherapy treatment in PTSD KEY INCLUSION CRITERIA Female and male (18-75 years) Current PTSD diagnosis CAPS-5 ≥ 30 (Screening & Baseline) (& ≤ 25% decrease Screening to Baseline) -25 Sites 欧 Topline data expected 1H'23#23Bionomics CNS-focused Collaborations CNS-focused 23#24Ongoing Strategic Collaboration with Merck & Co. MSD Collaboration Overview Development Updates Bionomics - Entered into in 2014 to develop a7 receptor PAMS targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions Merck funds all R&D activities including clinical development and WW commercialization of any products from collaboration Milestone payments of US$20M upfront and US$10M in 2017 when 1st compound entered Phase 1 clinical trials Eligible to receive up to US$465M in additional development and commercial milestone payments plus royalties Includes 2 candidates which are PAMs of the a7 receptor in early-stage Phase 1 safety and biomarker clinical trials for treating cognitive impairment The 1st compound has completed Phase 1 safety clinical trials in healthy subjects and there are ongoing plans for further biomarker studies In 2020, a second molecule that showed an improved potency profile in preclinical animal models was advanced by Merck into Phase 1 clinical trials MERCK PARTNERSHIP Snapshot of Early BNC375 Studies Recognition (%) 80- 60- 40- Veh Wang et al. J Pharmacol Exp Ther 373:311-324, May 2020 https://pubmed.ncbi.nlm.nih.gov/3.2094.294/ PAM- Positive alosteric modulator MSD - A trødename of Merck & Co., Inc, Kenilworth NY USA Scopolamine (1mpk, IP) -- 0.01 0.1 1 10 Don BNC375 (mg/kg, PO) % Correct Difficult Trials 100- 60- 40- 20 V 0 Scopolamine***** 0.1 BNC375 1 ng/kg, PO) 10 100- % correct Difficult Trials 50- BNC 375 (mg/kg, IM) 24#25MOU for BNC210 and MDMA Derivative (EMP-01) for Post-Traumatic Stress Disorder Joint Feasibility Assessment with: Empath Bio O EMP-01 = 3,4-Methylenedioxymethamphetamine (MDMA) derivative Bionomics ATAI LIFE SCIENCES DAILY NEWS Word • Business Finance Lifestyle Travel - Sport - Weather 22 February 2021 Illustrative Memorandum of Understanding with EmpathBio's MDMA Derivative Initial collaborative framework of preclinical studies to collectively explore a combination drug treatment regimen with BNC210 and EMP-01 MDMA-assisted psychotherapy has demonstrated significant symptom improvement in PTSD patients FDA has granted a Breakthrough Therapy designation to MDMA-assisted psychotherapy EmpathBio is developing MDMA derivatives that may permit the entactogenic effects of MDMA to be separated from some of the known adverse effects To explore the possibility of a combination treatment regimen warranting clinical evaluation 25#26Emerging CNS Pipeline for Partnering Bionomics 26#27Kv3.1 / Kv3.2 Ion Channel Activators for Cognitive Dysfunction and Negative Symptoms Promising therapeutic strategy for improving cognitive disfunction and social withdrawal symptoms -600 COMPOUNDS SYNTHESIZED 2 SERIES PATENTED Lead Compound BL-76 Bionomics Back-up Compounds 2 Patents Published Bionomics' molecules target Kv3.1/3.2 ion channels on parvalbumin positive, gabaergic interneurons in the pre-frontal cortex *Coswwwodas Potential in schizophrenia, Autism Spectrum disorders and conditions with cognitive impairments 40 Lead Compound BL-76 Fully Reverses PCP-induced Cognitive Deficit in Mice in the T-maze 100% -0%--75% - 43% -70%- 103% REVERSAL OF PCP EFFECTS Vehicle PCP 3 mg/kg 0 Risperidona 0.001 mg/kg (p IP CP BL-T6 jn glkg polPCP BL-76 10mg/kg po IP CP BL-78 30mg/kg po/PCP 27#28Pan Nav Inhibitors: Potential Non-Addictive, Reduced Side-Effect Chronic Pain Therapies Disease-Related Genetics BNO Pan Nav inhibitors Small molecules with functional selectivity for voltage gated sodium channels: Nav1.7, Nav 1.8 and potentially Nav1.9 Bionomics Gain & Loss-of-function mutations in Nav1.7, 1.8 and 1.9 1000+ COMPOUNDS SYNTHESIZED 2 SERIES PATENTED LEAD COMPOUND BL-017881 BACK-UP COMPOUNDS 3 Patents Published Associated with human pain syndromes where extreme pain or no pain is experienced Lead Candidate Identified BL-017881 OBSERVED TO REVERSE PAIN IN THE FORMALIN PAW MODEL IN MICE 28#29Investment Highlights & Stock and Financial Information Bionomics 29#30Stock and Financial Snapshot D Cash: US$16.4M (A$22.2M) Debt: $0 Shares Outstanding: ~1,007.6M (ASX:BNO) Warrants Outstanding: 166.1 (WAEP = US$0.08 / A$0.11)1 Significant Investors: ▪ Biotechnology Value Fund ▪ Apeiron Investment Group Ltd. ■ Merck & Co Bionomics Figures as of September 30, 2011 unsudited financials, Based on USD/AUD COMISION KON Kỷ 1. 28 1. Includes "16.1M warrants "US$0 43 / "A$0 57 exercise price expiring December 11, 2021 30#31Bionomics Outlook: Renewed Value-driving Trajectory Bionomics Bionomics Diversified model with multiple potential value-driving clinical milestones expected in the next 4 - 6 quarters alı BNC210's novel rapid onset formulation granted Fast Track designation for acute treatment of SAD Established clinical proof-of-concept¹; expect Phase 2 Study start by YE'21 & topline data YE'22 BNC210 Phase 2b ATTUNE PTSD study under way with Fast Track designation for 1H'23 topline data Tablet formulation achieves exposure projected from pharmacometric analysis Merck strategic partnership for treatment of cognitive impairment in Alzheimer's disease with two compounds in clinical development Diverse early-stage pipeline of partnering prospects targeting Kv and Nav ion channels for treatment of schizophrenia and pain, respectively 31 Well-capitalized balance sheet driven by experienced leadership SAD Social Awety Disorder PTSD-Post-Traumatic Stress Disorder Wise T. et ot, Bological Psychiatry 2020 (htte://del.org/10.1016/5 bltsych 2019. 12.013): Perki At of Transional Psychay 202T (htt://g/10.1038/541.398-020-01 14I-S)#32APPENDIX: BNC210 Prior Clinical Trial Information Bionomics 32#33Phase 1 1 1 1b 1b 1b 1 1 1 2a 2a 2 Summary of BNC210 Clinical Trials: Excellent Safety and Tolerability Profile in Healthy Subjects and Patients 2b Description Single Ascending Dose Safety and PK Single Ascending Dose Safety and PK; Food Effect Single Ascending Dose Safety and PK; Food Effect Lorazepam Comparison CCK-4 Panic Attack Model Multiple Ascending Dose Safety and PK; Expanded Cohort for EEG Target Engagement Suspension and Tablet Formulation PK Comparison Single Ascending Dose Safety and PK Multiple Dosing Safety and PK Imaging and Behavioral Study In Generalized Anxiety Disorder Agitation in the Elderly in Hospital Setting Bionomics Post-Traumatic Stress Disorder Post-Traumatic Stress Disorder EEG Electromorpholography Participants / Setting Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Generalized anxiety disorder patients /In-clinic P-Pharmacovic Agitated elderly patients/ Hospital Post-traumatic stress disorder patients/Out-patient The number of envolled subjects who were administered BWC210 other enrolled subjects were usted placebo only CON4-Cholecystok Tetappide Post-traumatic stress disorder patients/Out-patient Subjects Enrolled/ Administered BNC210 32/24 4/3 47/40 24/22 60/59 56/44 6/5 5/5 10/10 27/25 38/18 193/143 Ongoing BNC210 Formulation and Doses Suspension; single doses (5 to 2000 mg) Suspension; single doses (300 to 2000 mg) Capsule; single doses (300 to 3000 mg) Suspension; single doses (300 and 2000 mg) Suspension; single doses (2000 mg) Suspension; multiple doses (150 to 1000 mg twice daily for 8 days) Suspension and tablet; single doses (300 mg) Tablet; single doses (600 to 1200 mg) Tablet; multiple doses (900 mg twice daily for 7 days) Suspension; single doses (300 and 2000 mg) Suspension; multiple doses (300 mg twice daily for 5 days) Suspension; multiple doses (150, 300 or 600 mg twice daily for 12 weeks) Tablet; multiple doses (900 mg twice daily for 12 weeks) Location 33 Australia Australia US France France France Australia Australia Australia UK Australia Australia US US#34Phase 2 Trial of BNC210 in Adults with Post-Traumatic Stress Disorder (PTSD) restore 34 Multi-center, randomized, double-blind, placebo-controlled BNC210 150 mg, 300 mg, 600 mg and placebo (1:1:1:1) (liquid suspension formulation taken twice daily, b.i.d.) 12-week treatment period Bionomics i Study Design Key Selection Criteria Key Study Objectives • 193 participants 20 US sites/6 Australian sites Current diagnosis of PTSD as defined by CAPS-5 (Clinician- Administered PTSD Scale for DSM-5) • To assess the effects of BNC210 on investigator-rated symptoms of PTSD measured by CAPS-5 1 To assess the safety and tolerability of BNC210 in subjects with PTSD#35BNC210 PTSD Trial Overall Conclusions No overall effect on primary endpoint of CAPS-5 total severity score at 12 weeks Australian patients had a greater improvement over placebo than US patients ✓CAPS-5 statistically significant at Week 4 in Australians (p<0.05) Evidence of antidepressant effect in high dose treatment group in total population ✓CAPS-5 Criterion D overall (negative alterations in cognitions and mood) statistically significant at Week 1 (p<0.05) ✓CAPS-5 Criterion D, Question 2 (persistent and exaggerated negative beliefs or expectations) statistically significant at Week 1 (p=0.001) ✓CAPS-5 Criterion D, Question 4 (persistent negative emotional state) statistically significant at Weeks 4 and 8 (p<0.05) Trend for anxiolytic effect in high dose treatment group in the total population ✓ Trend towards improvement on CAPS-5 Criterion E (marked alterations in arousal and reactivity), Question 3 (hypervigilance) ✓Trend towards improvement on CAPS-5 Criterion E, Question 4 (exaggerated startle response) BNC210 was well tolerated in patients with PTSD ✓No trend for increased adverse events with treatment ✓No evidence of cognitive impairment ✓No evidence of suicidal ideation or behavior worsening restore Potential reasons why clinically significant effects and trends seen at early time points did not translate into significant primary endpoint on CAPS-5 at 12 Weeks • Inadequate overall blood exposure of BNC210 Lower compliance with liquid suspension formulation which needed to be taken with food Bionomics 35#36Mechanistic Validation of BNC210 as Evidenced by EEG Response BNC210 blood-brain barrier penetration and nicotinic receptor target engagement in humans Bionomics Power in alpha2 band BNC210 Reduced Nicotine-induced EEG Responses EEG Electroencephotography ** p-value less than 0.01 1.5. 1.0- 0.5- 0.0 0.0 ACHR=Nicotini Acetylcholine Receptor Day -1 without BNC210 Day 7 with BNC210 NS 0.5 p=0.0062 1.0 Nicotine (mg) p=0.0026 1.5 p=0.0487 2.0 Activation of nicotinic receptors in the brain induces EEG response x432 and a7 receptors are the major nACHR populations targeted BNC210 daily oral dosing reduced nicotine-induced EEG in the a 2 band Observed reduction in EEG response, potentially due to BNC210's negative allosteric modulation of the a7 receptors 36#37APPENDIX: Building Value Through Legacy Oncology Assets Bionomics 37#38Legacy Oncology Asset Monetization to Drive Value: BNC101 Exclusive BNC101 Oncology License Agreement for the Development of CAR-T Therapeutics Bionomics carina biotech Exclusive Agreement to license Bionomics' BNC 101 oncology drug candidate to Carina Biotech for the development of Chimeric Antigen Receptor T cell (CAR-T) therapy, which harnesses the body's immune system to fight cancer. Bionomics is eligible to receive up to A$118 million in clinical & development milestones plus royalty payments if Carina fully develops and markets the new therapy. In the event that Carina sub-licenses the CAR-T treatment, Bionomics is eligible to share in the sub-licensing revenues in early clinical development and receive a substantial double-digit portion of the revenues in later stages of clinical development. In September 2021, Carina announced that it plans to initiate a clinical trial of BNC101 CAR-T therapy for the treatment of advanced colorectal (bowel) cancer in late 2022 Bionomics retains BNC 101 for other types of therapies 38